로딩 중…
지수 로딩 중…
Remed Co.,Ltd.
302550· KOSDAQ· Health Care· Health Care Equipment & Services
₩2,840-4.54%
2026-06-19
Price Chart
Remed Co.,Ltd.-25.46%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 87.78B KRW |
| Revenue | 25.24B KRW |
| Net Income | -211.0M KRW |
| Total Assets | 54.74B KRW |
| Net Assets | 39.24B KRW |
| Employees | 104 |
| Value | |
| P/B | 2.24x |
| P/S | 3.48x |
| EV/EBITDA | 219.99x |
| Profitability | |
| ROE | -0.54% |
| ROA | -0.39% |
| Op. Margin | 1.42% |
| Revenue Growth | 11.37% |
| Earnings Growth | 123.66% |
| Financial Health | |
| Debt Ratio | 139.51% |
| Total Debt | 1.12B KRW |
| Cash | 10.12B KRW |
| Current Ratio | 2.75x |
| Net Debt/EBITDA | -25.13x |
| Performance | |
| 1Y Return | -25.46% |
| 1M Return | 1.43% |
| From 52W High | -38.19% |
| 1Y MDD | -33.25% |
| Trading | |
| Volume | 92,365 shares |
| Foreign Own. | 0.48% |
| Per Share | |
| EPS | 38 KRW |
| BPS | 1,309 KRW |
Company Info
REMED, established in 2003 and headquartered in Cheongju-si, Chungcheongbuk-do, develops and manufactures non-invasive medical devices that induce nerve cell depolarization using strong magnetic fields. The company operates in brain rehabilitation, chronic pain treatment, and aesthetics, with its neuromodulation device for chronic pain treatment and transcranial magnetic stimulation device for brain rehabilitation having received U.S. FDA approval in 2021. REMED is targeting the global market by entering the U.S. market for TMS for depression treatment, expanding sales internationally, conducting clinical trials for mental illnesses, and premiumizing Peripheral Magnetic Stimulation products.